A Phase 2 Study of Nivolumab Using a Fixed Dose of 40 mg (Nivo40) in Patients With Relapsed/Refractory Hodgkin Lymphoma
暂无分享，去创建一个
L. Stelmakh | I. Moiseev | B. Afanasyev | K. Lepik | E. Babenko | A. Kulagin | M. Popova | N. Mikhailova | E. Kondakova | V. Baykov | L. Fedorova | N. Volkov | P. Kotselyabina | A. Beynarovich | Y. Zalyalov | E. Lepik